On October 13, 2025, Waters Corporation announced the launch of its Xevo Charge Detection Mass Spectrometer (CDMS), a first‑of‑its‑kind system that delivers direct, individual‑particle mass measurement for biomolecules up to 150 MDa. The announcement, issued via PR Newswire on October 14, 2025, states that the CDMS is available to order immediately and is powered by the GxP‑ready waters_connect software.
The CDMS employs an Electrostatic Linear Ion Trap (ELIT) to simultaneously measure mass‑to‑charge ratio and mass, enabling confident analysis of complex molecules such as protein complexes, nucleic acids, lipid nanoparticles, and viral vectors. The technology, acquired from Indiana University in 2022, allows analysis with up to 100‑fold less sample volume and delivers results in less than ten minutes, even at concentrations as low as 10^10 vp/mL.
By providing a rapid, high‑resolution characterization platform for next‑generation therapeutics, the CDMS expands Waters’ portfolio into the rapidly growing gene and cell therapy markets. The system’s ability to analyze empty, partial, and full viral vector capsids in real time supports process development, regulatory approval, and manufacturing, positioning Waters to capture a share of the expanding biotherapeutics analytical services market.
The launch underscores Waters’ strategic focus on large‑molecule analysis and reinforces its leadership in regulated analytical solutions. Customers can now order the Xevo CDMS directly, and the company anticipates that the new platform will drive additional revenue streams in the coming quarters as demand for advanced biotherapeutic characterization grows.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.